Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | TDO2 | P48775 | 2/20 | 0.48 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516801 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AIDO1TDO2MAOA | |
| SCHEMBL157927 | 1.00 | ADRB2 (0.56) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL1887841 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL1002687 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Iodide SCHEMBL28918391 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Bromide SCHEMBL25231048 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL14576625 | 0.97 | ADRB2 (0.54) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL29227874 | 0.91 | ADRB2 (0.48) | ADRB2PDE2AIDO1TDO2MAOA | |
| Hydrochloric Acid SCHEMBL30939459 | 0.91 | ADRB2 (0.48) | ADRB2PDE2AIDO1TDO2MAOA | |
| SCHEMBL4380562 | 0.87 | SOS1 (0.46) | ADRB2PDE2AIDO1TDO2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 734 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119119035-A | RIPK1 kinase target inhibitor and preparation method and application thereof | 中山大学 | 2024-12-13 | — | — | CN | claimed |
| CN-112430247-B | Perovskite nanocrystalline material with circular polarization luminescence and up-conversion circular polarization luminescence properties and preparation method and application thereof | 国家纳米科学中心 | 2022-12-09 | — | — | CN | claimed |
| CN-112430247-A | Perovskite nanocrystalline material with circular polarization luminescence and up-conversion circular polarization luminescence properties and preparation method and application thereof | 国家纳米科学中心 | 2021-03-02 | — | — | CN | claimed |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | AbbVie Deutschland GmbH & Co. KG (DE) | 2018-04-12 | — | — | US | claimed |
| EP-2780324-B1 | HETEROCYCLIC CARBOXAMIDES USEFUL AS INHIBITORS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE DEUTSCHLAND (DE) | 2017-05-17 | — | — | EP | claimed |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | ABBVIE INC. | 2016-11-03 | — | — | US | claimed |
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | H. LUNDBECK A/S (DK) | 2015-11-05 | — | — | US | claimed |
| EP-2928860-A1 | NEW POSITIVE ALLOSTERIC MODULATORS OF NICOTINIC ACETYLCHOLINE RECEPTOR | H. Lundbeck A/S (DK) | 2015-10-14 | — | — | EP | claimed |
| US-9133187-B2 | Serine/threonine kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2015-09-15 | — | — | US | claimed |
| CN-104666299-A | 4-(azacycloalkyl)benzene-1,3-diol compounds as tyrosinase inhibitors, process for the preparation thereof and use thereof | GALDERMA RES & DEV | 2015-06-03 | — | — | CN | claimed |
| WO-2008064255-A2 | COMPOUNDS MODULATING C-FMS AND/OR C-KIT ACTIVITY AND USES THEREFOR | PLEXXIKON, INC. (US) | 2008-05-29 | — | — | WO | claimed |
| EP-1427727-B1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | PROCTER & GAMBLE (US) | 2005-01-26 | — | — | EP | claimed |
| EP-1485167-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | The Procter & Gamble Company (US) | 2004-12-15 | — | — | EP | claimed |
| US-6821971-B2 | FOR PROPHYALXIS OF RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE (IBS), SEPTIC SHOCK, CARDIOPULMONARY DYSFUNCTION, ACUTE RESPIRATORY DISEASE, CACHEXIA | THE PROCTER & GAMBLE COMPANY | 2004-11-23 | — | — | US | claimed |
| EP-1427727-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2004-06-16 | — | — | EP | claimed |
| US-6677337-B2 | RHEUMATOID ARTHRITIS, OSTEOARTHRITIS, INFLAMMATORY BOWEL DISEASE, CACHEXIA, SEPTIC SHOCK, CARDIOVASCULAR AND RESPIRATORY SYSTEM DISORDERS | THE PROCTER & GAMBLE COMPANY | 2004-01-13 | — | — | US | claimed |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | PROCTER & GAMBLE COMPANY, THE | 2003-12-04 | — | — | US | claimed |
| WO-2003080184-A1 | 1,2-DIHYDROPYRAZOL-3-ONES AS CYTOKINE MEDIATORS | THE PROCTER & GAMBLE COMPANY (US) | 2003-10-02 | — | — | WO | claimed |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | THE PROCTER & GAMBLE COMPANY | 2003-06-05 | — | — | US | claimed |
| WO-2003024970-A1 | COMPOUNDS WHICH INHIBIT THE RELEASE OF INFLAMMATORY CYTOKINES | THE PROCTER & GAMBLE COMPANY (US) | 2003-03-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150315130-A1 | New positive allosteric modulators of nicotinic acetylcholine receptor | CHRNG, CHRNA7, CHRNA1 | ADRB2 77/4885PDE2A 564/4885IDO1 3189/4885 |
| US-20030105084-A1 | Compound which inhibit the release of inflammatory cytokines | IL1B, IL1A, TNF | ADRB2 205/4885PDE2A 1106/4885IDO1 132/4885 |
| US-20160318871-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | ADRB2 249/4885PDE2A 4/4885IDO1 287/4885 |
| US-20180099936-A1 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | PDE3A, PDE5A, PDE3B | ADRB2 254/4885PDE2A 4/4885IDO1 291/4885 |
| US-20030225082-A1 | 1,2-dihydropyrazol-3-ones which controls inflammatory cytokines | IL1B, IL1A, IL1R1 | ADRB2 407/4885PDE2A 971/4885IDO1 154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.